AI-Powered texts aim to help smokers beat the habit

NCT ID NCT04720625

First seen Jul 31, 2026 ยท Last updated Jul 31, 2026

Summary

This trial tests a computer program called Adapt2Quit that sends personalized motivational text messages to help smokers quit. The messages are chosen based on how each participant rates them, aiming to be more effective than standard quitline texts. The study involves socioeconomically disadvantaged smokers who are current smokers and have a texting-enabled phone. The main goal is to see if these tailored messages lead to more people quitting smoking, verified by breath tests at six months.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Adapt2Quit, a machine-learning system that sends personalized motivational text messages to help smokers quit
What this could lead to
If effective, this approach could offer a low-cost, scalable way to help socioeconomically disadvantaged smokers quit, reducing smoking-related health disparities.
What could go wrong
The trial is testing a behavioral intervention, and results may vary. Success depends on engagement and may not generalize to all smokers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOBACCO SMOKING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tobacco Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Baystate Health

    Springfield, Massachusetts, 01199, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • University of Massachusetts Medical School

    Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.